1445993-26-9

Basic information

• Product Name: ABBV-075
• Synonyms: N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide;ABBV-075;Mivebresib;Mivebresib (ABBV-075 )
• CAS NO: 1445993-26-9
• Molecular Formula: C₂₂H₁₉F₂N₃O₄S
• Molecular Weight: 459.4657664
• Mol File: 1445993-26-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 608.9±65.0 °C(Predicted)
• Appearance: /
• Density: 1.465±0.06 g/cm3(Predicted)
• PKA: 8.37±0.10(Predicted)
• CAS DataBase Reference: ABBV-075(CAS DataBase Reference)
• NIST Chemistry Reference: ABBV-075(1445993-26-9)
• EPA Substance Registry System: ABBV-075(1445993-26-9)

Safety Data

• Hazardous Substances Data: 1445993-26-9(Hazardous Substances Data)

Usage

General Description

ABBV-075 is a novel, orally bioavailable Wnt pathway inhibitor that has shown promising results in preclinical studies for the treatment of various cancers. It is a small molecule inhibitor of the Wnt signaling pathway, which is involved in cell growth and proliferation. ABBV-075 has demonstrated potent anti-tumor activity in multiple cancer models, including solid tumors and hematologic malignancies, by inhibiting the growth of cancer cells and inducing apoptosis. Additionally, it has shown synergistic effects when combined with other anticancer agents, making it a potential candidate for combination therapy. Its ability to target the Wnt pathway, which is overactive in many types of cancer, makes ABBV-075 a promising candidate for further clinical development and potential treatment of cancer.

Upstream product

• 1445994-28-4 4-(5-amino-2-(2,4-difluorophenoxy)phenyl)-6-methyl-1H-pyrrolo[2,3-c]pyridine-7(6H)-one 
• 594-44-5 Ethanesulfonyl chloride 
• 1445993-88-3 4-(2-fluoro-5-nitrophenyl)-6-methyl-1-tosyl-1H-pyrrolo[2,3-c]-pyridin-7(6H)-one 
• 1446235-98-8 4-[5-amino-2-(2,4-difluorophenoxy)phenyl]-6-methyl-1-tosyl-1,6-dihydro-7H-pyrrolo[2,3-c] pyridin-7-one 
• 1445993-89-4 6-methyl-1-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 701-45-1 2-bromo-1-fluoro-4-nitrobenzene 
• 884495-14-1 5-bromo-2-methoxy-4-methyl-3-nitropyridine 
• 1445993-87-2 4-bromo-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 1445993-86-1 4-bromo-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 1445993-85-0 4-bromo-7-methoxy-1-(4-methylbenzenesulfonyl)pyrrolo[2,3-c]pyridine 
• 367-27-1 2,4-difluorophenol 
• 425380-37-6 4-bromo-7-methoxy-1-hydro-pyrrolo[2,3-c]pyridine 

Downstream Products

• 1446235-29-5 N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-N-[2-(dimethylamino)ethyl]ethanesulfonamide 
• 1446235-81-9 N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-N-(2-methoxyethyl)ethanesulfonamide 

Relevant articles and documents

Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor

The development of bromodomain and extraterminal domain (BET) bromodomain inhibitors and their examination in clinical studies, particularly in oncology settings, has garnered substantial recent interest. An effort to generate novel BET bromodomain inhibi

BROMODOMAIN INHIBITORS

Provided are compounds of formula (I), wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).